Sugi Predict

Sugi Predict / Compounds / SCHEMBL12634799

SCHEMBL12634799

SCHEMBL12634799

Fc1cc(-c2nc(Cl)c3c(n2)CCCC3)c(F)cc1Cl

nearest known ligand 0.38

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SOS1 Q07889 1/20 0.38
▸ ACHE P22303 12/20 0.37
▸ MAPT P10636 1/20 0.36
▸ BCHE P06276 7/20 0.35
▸ GRIN1 Q05586 6/20 0.35
▸ GRIN2A Q12879 6/20 0.35
▸ TP53 P04637 2/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ NSD2 O96028 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ EPHX2 P34913 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12634769 0.97 SOS1 (0.35) SOS1ACHEMAPTBCHEGRIN1
SCHEMBL12634767 0.88 ACHE (0.36) SOS1ACHEBCHEGRIN1GRIN2A
SCHEMBL12634772 0.83 ACHE (0.35) ACHEBCHEGRIN1GRIN2ATP53
SCHEMBL2200699 0.82 SOS1 (0.45) SOS1ACHEMAPTBCHEGRIN1
SCHEMBL7506685 0.81 ACHE (0.46) SOS1ACHEBCHEGRIN1GRIN2A
SCHEMBL12426347 0.79 ACHE (0.44) SOS1ACHEMAPTBCHEGRIN1
SCHEMBL12634796 0.78 CYP1A2 (0.36) CYP1A2
SCHEMBL1882382 0.78 CYP1A2 (0.33) CYP1A2
SCHEMBL14463345 0.78 ACHE (0.46) SOS1ACHEBCHEGRIN1GRIN2A
SCHEMBL1879354 0.76 CYP1A2 (0.32) CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947690-B2 Insulin secretagogue and hypoglycemic agent; pyrimidine derivatives condensed with a non-aromatic ring selected from dihydrothiophene, dihydrofuran, cycloalkane moiety; 1-[2-(4-chloro-2,5-difluorophenyl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl]-4-(3-hydroxypropyl)piperidin-4-ol for example ASTELLAS PHARMA INC. (JP) 2011-05-24 — — US disclosed
US-7947690-B2 Insulin secretagogue and hypoglycemic agent; pyrimidine derivatives condensed with a non-aromatic ring selected from dihydrothiophene, dihydrofuran, cycloalkane moiety; 1-[2-(4-chloro-2,5-difluorophenyl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl]-4-(3-hydroxypropyl)piperidin-4-ol for example ASTELLAS PHARMA INC. (JP) 2011-05-24 — — US disclosed
US-20080070896-A1 Pyrimidine Derivative Condensed with a Non-Aromatic Ring ASTELLAS PHARMA INC. (JP) 2008-03-20 — — US disclosed
US-20080070896-A1 Pyrimidine Derivative Condensed with a Non-Aromatic Ring ASTELLAS PHARMA INC. (JP) 2008-03-20 — — US disclosed
EP-1803710-A1 PYRIMIDINE DERIVATIVE CONDENSED WITH NON-AROMATIC RING Astellas Pharma Inc. (JP) 2007-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070896-A1 Pyrimidine Derivative Condensed with a Non-Aromatic Ring GPR119, IRS1, NONO SOS1 2777/4885ACHE 3983/4885MAPT 1944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.